Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD)

First Page		Document Content
Date: 2015-11-05 09:21:27 Allergology Immunology Immune system RTT Type I hypersensitivity Allergen immunotherapy Allergen Allergic conjunctivitis Allergic rhinitis Immunoglobulin E Allergy Rhinitis		Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD) Add to Reading List Source URL: www.circassia.com Download Document from Source Website File Size: 43,28 KB Share Document on Facebook

	Reduction of Allergy Symptoms by Molekule’s PECO AIR Purification By: Dr. Nikhil G. Rao Abstract: Exposure to airborne allergens and pollutants is linked to symptom severity for allergic rhinitis and DocID: 1uuhF - View Document
	20160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial DocID: 1rovF - View Document
	Article ID: WMC005078 ISSNSensitization pattern to food and inhalant allergens in allergic patients from Jeddah city: Saudi Arabia DocID: 1r2Hj - View Document
	Indoor Air 2008, 17-22 August 2008, Copenhagen, Denmark - Paper ID: 458 The perceived indoor climate in Swedish schools Kjell Andersson*, Inger Fagerlund and Wenche Aslaksen Department of Occupational and Environmental DocID: 1qgNX - View Document
	Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT − Dose assessment for upcoming Phase III trial EPALINGES, Switzerland, December 11, 2014 – Anergis, a company developing proprietary DocID: 1q3c9 - View Document